ArticleScientific reports2026
Five-variable nomogram including PR interval and left atrial appendage flow velocity predicts atrial fibrillation recurrence after cryoballoon ablation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cryoballoon ablation for atrial fibrillation (AF) carries a non-negligible 1-year recurrence risk, and existing risk models often omit electrocardiographic and echocardiographic features. We aimed to develop and internally validate an AF recurrence prediction model that integrates the PR interval and echocardiographic measures—left atrial dimension (LAD) and left atrial appendage flow velocity (LAAFV)—with clinical characteristics. In this single-center retrospective cohort of 757 patients who underwent first-time cryoballoon ablation (2017–2023), participants were randomly divided into training (70%) and validation (30%) sets. Candidate predictors were selected via least absolute shrinkage and selection operator (LASSO) and random forest. Model performance was evaluated at prespecified 12- and 24-month horizons with time-dependent receiver operating characteristic (ROC) curves, calibration, decision curve analysis, and Kaplan–Meier estimates. Fiveindependently associated predictors were identified: female sex, persistent AF, prolonged PR interval, increased LAD, and reduced LAAFV. A multivariable Cox proportional hazards model was used to construct the nomogram. Head-to-head benchmarking against APPLE, SUCCESS, PAT2C2H, HATCH, BASE-AF2, and CHA₂DS₂-VASc was performed within the same participants via two-sided paired DeLong tests with Holm correction. The nomogram showed strong discrimination (AUC 0.81 and 0.83 in training; 0.82 and 0.80 in validation at 12 and 24 months, respectively) and outperformed all comparators at both horizons (Holm-adjusted P < 0.01). Risk stratification separated the low-, intermediate-, and high-risk groups, with 24-month recurrence-free survival rates of approximately 80%, 45%, and 20%, respectively. By combining structural and functional atrial parameters with clinical features, this tool enhances the prediction of AF recurrence after cryoballoon ablation and may inform individualized postablation management. Prospective multicenter external validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.